B-J Kim1, H J Yoo2, S J Park3, M K Kwak4, S H Lee4, S J Kim2, M W Hamrick5, C M Isales6, S H Ahn7, J-M Koh4. 1. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. umkbj0825@amc.seoul.kr. 2. Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3. Asan Institute for Life Sciences, Seoul, South Korea. 4. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. 5. Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta University, Augusta, GA, USA. 6. Department of Orthopedic Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA. 7. Department of Endocrinology, Inha University School of Medicine, Incheon, South Korea.
Abstract
The plasma n-3 fatty acid level was 26.2% lower in patients with osteoporotic hip fracture than in those with osteoarthritis. In all patients, n-3 fatty acid was positively associated with bone mineral density and inversely associated with tartrate-resistant acid phosphatase-5b level in bone marrow aspirates, reflecting the bone microenvironment. INTRODUCTION: Despite the potential beneficial role of n-3 fatty acid (FA) on bone metabolism, the specific mechanisms underlying these effects in humans remain unclear. Here, we assessed whether the plasma n-3 level, as an objective indicator of its status, is associated with osteoporosis-related phenotypes and bone-related markers in human bone marrow (BM) samples. METHODS: This was a case-control and cross-sectional study conducted in a clinical unit. n-3 FA in the blood and bone biochemical markers in the BM aspirates were measured by gas chromatography/mass spectrometry and immunoassay, respectively. BM fluids were collected from 72 patients who underwent hip surgery because of either osteoporotic hip fracture (HF; n = 28) or osteoarthritis (n = 44). RESULTS: After adjusting for confounders, patients with HF had 26.2% lower plasma n-3 levels than those with osteoarthritis (P = 0.006), and each standard deviation increment in plasma n-3 was associated with a multivariate-adjusted odds ratio of 0.40 for osteoporotic HF (P = 0.010). In multivariate analyses including all patients, a higher plasma n-3 level was associated with higher bone mass at the lumbar spine (β = 0.615, P = 0.002) and total femur (β = 0.244, P = 0.045). Interestingly, the plasma n-3 level was inversely associated with the tartrate-resistant acid phosphatase-5b level (β = - 0.633, P = 0.023), but not with the bone-specific alkaline phosphatase level, in BM aspirates. CONCLUSIONS: These findings provide clinical evidence that n-3 FA is a potential inhibitor of osteoclastogenesis that favors human bone health.
The plasma n-3 fatty acid level was 26.2% lower in patients with osteoporotic hip fracture than in those with osteoarthritis. In all patients, n-3 fatty acid was positively associated with bone mineral density and inversely associated with tartrate-resistant acid phosphatase-5b level in bone marrow aspirates, reflecting the bone microenvironment. INTRODUCTION: Despite the potential beneficial role of n-3 fatty acid (FA) on bone metabolism, the specific mechanisms underlying these effects in humans remain unclear. Here, we assessed whether the plasma n-3 level, as an objective indicator of its status, is associated with osteoporosis-related phenotypes and bone-related markers in human bone marrow (BM) samples. METHODS: This was a case-control and cross-sectional study conducted in a clinical unit. n-3 FA in the blood and bone biochemical markers in the BM aspirates were measured by gas chromatography/mass spectrometry and immunoassay, respectively. BM fluids were collected from 72 patients who underwent hip surgery because of either osteoporotic hip fracture (HF; n = 28) or osteoarthritis (n = 44). RESULTS: After adjusting for confounders, patients with HF had 26.2% lower plasma n-3 levels than those with osteoarthritis (P = 0.006), and each standard deviation increment in plasma n-3 was associated with a multivariate-adjusted odds ratio of 0.40 for osteoporotic HF (P = 0.010). In multivariate analyses including all patients, a higher plasma n-3 level was associated with higher bone mass at the lumbar spine (β = 0.615, P = 0.002) and total femur (β = 0.244, P = 0.045). Interestingly, the plasma n-3 level was inversely associated with the tartrate-resistant acid phosphatase-5b level (β = - 0.633, P = 0.023), but not with the bone-specific alkaline phosphatase level, in BM aspirates. CONCLUSIONS: These findings provide clinical evidence that n-3 FA is a potential inhibitor of osteoclastogenesis that favors human bone health.
Entities:
Keywords:
Bone mass; Bone resorption; Osteoporotic fracture; n-3 fatty acid
Authors: Jyrki K Virtanen; Dariush Mozaffarian; Jane A Cauley; Kenneth J Mukamal; John Robbins; David S Siscovick Journal: J Bone Miner Res Date: 2010-09 Impact factor: 6.741
Authors: Orlagh Feehan; Pamela Jane Magee; Laura Kirsty Pourshahidi; David John Armstrong; Mary Martina Slevin; Philip James Allsopp; Marie Catherine Conway; J J Strain; Emeir Mary McSorley Journal: Eur J Nutr Date: 2022-07-30 Impact factor: 4.865
Authors: Il-Young Jang; Hee-Won Jung; Jin Hoon Park; Jeoung Hee Kim; Seungjoo Lee; Eunju Lee; Jin Young Lee; So Jeong Park; Da Ae Kim; Su Jung Kim; Hyun Ju Yoo; Beom-Jun Kim Journal: Nutrients Date: 2020-09-27 Impact factor: 5.717